SESSION TITLE: Airways 1
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Revefenacin (pINN), a novel nebulized long-acting muscarinic antagonist (LAMA) in development for management of chronic obstructive pulmonary disease (COPD), produces sustained bronchodilation with limited systemic side effects. To characterize the dose-response profile for revefenacin, we completed a 28-day study, evaluating a dose range from 44 µg to 350 µg, in participants with COPD.